Adjuvant_chemotherapy_in_early_breast_cancer_and_incidence_of_new_primary_malignancies._Adjuvant_chemotherapy_is_increasingly_being_given_to_patients_with_early_breast_cancer._Long-term_follow-up_studies_suggest_a_higher_frequency_of_secondary_tumours,_especially_leukaemias,_among_women_receiving_such_cytotoxic_drugs._We_studied_the_frequency_of_new_primary_malignancies_in_1113_patients_with_early_breast_cancer_who_had_been_included_in_a_randomised_trial_to_compare_chemotherapy_as_an_adjunct_to_primary_surgery_with_adjuvant_locoregional_radiotherapy._The_estimated_rate_of_new_primary_malignancies_at_ten_years_was_significantly_lower_(p_less_than_0.0003)_in_the_chemotherapy_group_(1%)_than_in_the_radiotherapy_group_(6%)._The_corresponding_rate_among_1986_patients_treated_with_surgery_alone_was_5%._Our_findings_suggest_that_adjuvant_chemotherapy_in_early_breast_cancer_may_protect_against_the_development_of_new_primary_tumours_in_the_first_ten_years_of_follow-up.